Articles by James C. Greenwood - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

Keyword Location
About Search
Articles by James C. Greenwood

Prescribing Caution for Biosimilars

Apr 2, 2013

Sound policies are needed to govern the substitution of interchangeable biologics.

Intellectual Property as the Foundation of Innovation

Supportive public policy is needed in order for innovation to flourish.
Dec 2, 2010

Supportive public policy is needed in order for innovation to flourish.

Delivering on the Promise of Biotechnology

The BIO convention, and healthcare reform, could re-energize biotech.
Apr 2, 2010

The BIO convention, and healthcare reform, could re-energize biotech.

Healthcare Reform Requires Room for Innovation

To move from R&D to breakthrough drugs, biotech companies need policies that support innovation.
Jan 2, 2010

To move from R&D to breakthrough drugs, biotech companies need policies that support innovation.

Progress Made on the Path to Biosimilars

BIO supports recent Congressional action toward a 12-year data exclusivity period for innovators.
Oct 2, 2009

BIO supports recent Congressional action toward a 12-year data exclusivity period for innovators.

Biotechnology in 2009

The president of BIO proposes the ingredients needed for industry growth.
May 2, 2009

The president of BIO proposes the ingredients needed for industry growth.

Industry Leaders Debate Follow-on Biologics Pathway

The organizations' presidents discuss market exclusivity, approval processes, and pending legislation.
May 2, 2009

The organizations' presidents discuss market exclusivity, approval processes, and pending legislation.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
FindPharma Custom Search
Click here